SCHEMBL7714636

SCHEMBL7714636

NS(=O)(=O)c1cccc2[nH]c3ccccc3c12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.56
IMPDH1 P20839 1/20 0.56
CA2 P00918 4/20 0.53
CA1 P00915 3/20 0.53
CA9 Q16790 2/20 0.53
CDK2 P24941 2/20 0.47
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 2/20 0.46
GPR3 P46089 1/20 0.46
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
GABRA3 P34903 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
GABRA4 P48169 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6686773 0.84 PARP1 (0.54) CA2CA1CA9CDK2ALDH1A1
SCHEMBL633783 0.84 IMPDH2 (0.55) IMPDH2IMPDH1CDK2ALDH1A1HSD17B10
SCHEMBL2026877 0.80 CA1 (0.52) CA2CA1CA9CDK2ALDH1A1
Carbazole SCHEMBL16345387 0.74 ALDH1A1 (0.64) IMPDH2IMPDH1ALDH1A1HSD17B10GPR3
SCHEMBL16530066 0.73 CA9 (0.44) CA2CA1CA9CDK2ALDH1A1
SCHEMBL29380761 0.73 ALDH1A1 (0.68) IMPDH2IMPDH1CDK2ALDH1A1HSD17B10
SCHEMBL1635466 0.73 ALDH1A1 (0.68) IMPDH2IMPDH1CDK2ALDH1A1HSD17B10
SCHEMBL9138970 0.73 CDK2 (0.78) CA2CA1CA9CDK2HSD17B10
SCHEMBL420335 0.72 IMPDH2 (0.59) IMPDH2IMPDH1CDK2ALDH1A1HSD17B10
SCHEMBL4896807 0.72 IMPDH2 (0.59) IMPDH2IMPDH1CA9CDK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0293716-A2 Polyhydrobenz(c,d)indolsulfonamides BAYER AG (DE) 1988-12-07 EP claimed
US-6376523-B1 HYPOTENSIVE AGENTS; ANTIINFLAMMATORY AGENTS; ENDOGENOUS VASOCONSTRUCTION PEPTIDE TEXAS BIOTECHNOLOGY CORPORATION 2002-04-23 US disclosed
US-20010036958-A1 Benzenesulfonamides and the use thereof to modulate the activity of endothelin ENCYSIVE PHARMACEUTICALS, INC. 2001-11-01 US disclosed
US-6030991-A ADJUSTING THE BINDING OF AN ENDOTHELIN PEPTIDE TO ENDOTHELIN A OR, PARTICULARLY, ENDOTHELIN B RECEPTORS, I.E. INHIBITING OR STIMULATING; ANTIINFLAMMATORY AGENT; ASTHMA; KIDNEYS; GASTROINTESTINAL, CARDIOASCULAR DISORDERS; HYPOTENSIVE AGENTS TEXAS BIOTECHNOLOGY CORP. (US) 2000-02-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036958-A1 Benzenesulfonamides and the use thereof to modulate the activity of endothelin EDNRB, EDNRA, ECE1 IMPDH2 3145/4885IMPDH1 3191/4885CA2 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.